Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy

Journal of Endocrinological Investigation

Volumn 20, Issue 7, 1997, Pages 373-379

  Custro, N ^a,b   Montalto, G ^a   Scafidi, V ^a   Soresi, M ^a   Gallo, S ^a   Tripi, S ^a   Notarbartolo, A ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Istituto di Medicina Interna e Geriatria   (Italy)

Author keywords

Alpha interferon; Autoimmune thyrolditis; Chronic hepatitis C; Hyperthyroidism; Hypothyroidism; Thyroid autoantibodies

Indexed keywords

AUTOANTIBODY; LYMPHOBLAST INTERFERON; RECOMBINANT ALPHA2A INTERFERON; TAUROURSODEOXYCHOLIC ACID; THIAMAZOLE; THYROID ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; ALPHA INTERFERON; ALPHA2A INTERFERON; IODIDE PEROXIDASE; LIOTHYRONINE; THYROXINE;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPIDEMIOLOGY; FEMALE; GRAVES DISEASE; HEPATITIS C; HUMAN; HYPOTHYROIDISM; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RISK; SIDE EFFECT; THYROID DISEASE; THYROID FUNCTION TEST; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME; AUTOIMMUNE DISEASE; BLOOD; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; THYROID GLAND;

ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; IODIDE PEROXIDASE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THYROID DISEASES; THYROID GLAND; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0030845861     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03347987     Document Type: Article

References (30)

1. Renault P.F., Hoofnagle J.H. Side effects of alpha Interferon. Semin. Liver Dis. 9: 273, 1989.
2. Conlon K.C., Urba W.J., Smith J.W., Steis R.G., Longo D.L., Clark J.W. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65: 2237, 1990.
3. Ronnblom L.E., Alm G.V., Oberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 115: 178, 1991.
4. Gisslinger H., Gilly B., Woloszczuk W., Mayr W.R., Havelec L., Linke W., Weissel M. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin. Exp. Immunol. 90: 363, 1992.
5. Marcelli R., Preziati D., Persani L., Rumi M.G., Del Ninno E., Beck-Peccoz P., Colombo M. High prevalence of thyroid dysfunction in patients with HCV infection treated with Interferon alpha 2a (IFN). It. J. Gastroenterol. 24: 288, 1992.
6. Roti E., Minnelli R., Giuberti T., Marchelli S., Schianchi C., Gardini E., Salvi M. Fiaccadori F., Ugolotti G., Neri T.M., Braverman L.E. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon alpha. Am. J. Med. 101: 482, 1996.
7. Tsianos V.E., Dalekos G.N., Merkouropoulos M.H., Tsatsoulis A.A. Seferiadis K.I. Frequency of thyroid dysfunction after recombinant alpha-interferon therapy in Greek patients with chronic active hepatitis. Eur.J. Gastroenterol. Hepatol. 6: 547, 1994.
8. Di Bisceglie A.M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J. Recombinant alpha interpheron therapy for chronic hepatitis C. A randomized, double blind, placebo-controlled trial. N. Engl. J. Med. 321: 1506, 1989.
9. Marcellin P., Pouteau M., Renard P., Grynblat J.M., Colas Linhart N., Bardet P., Bok, Benhamou J.P. Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut 33: 855, 1992.
10. Berris B., Feinman V.S. Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Digest. Dis. Sci. 36: 1657, 1991.
11. Lisker-Melman M., Di Bisceglie A.M., Usala S.J., Weintraub B., Murray L.M., Hoofnagle J.H. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alpha. Gastroenterology 102: 2155, 1992.
12. Marcellin P., Pouteau M., Messia O., Bok B., Erlinger S., Benhamou J.P. Virus de l'hépatite C, interféron alpha et dysthyroidie. Gastroenterol. Clin. Biol. 17: 887, 1993.
13. Tran A., Quaranta J.F., Benzaken S., Thiers V., Chau H.T., Hastier P., Regnier D., Dreyfus G., Pradier C., Sadoul J.L., Hebuterne X., Rampai P. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 18: 253, 1993.
14. Durazzo M., Gallone G., Costa C., Scaglione L., Sacchi C., Rossi P.P., Grassi A., Clerico A., Mazzillo A., Touscoz A.G., Fonzo D., Pagano G., Rizzetto M. Thyroid disorders and HCV infection (Abst). J. Hepatol. 21 (Suppl. 1): 173, 1994.
15. Watanabe U., Hashimoto E.,Hisamitsu T., Obata H., Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic C-hepatitis. Am. J. Gastroenterol. 89: 399, 1994.
16. Imagawa A., Itoh N. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic type C-hepatitis. J. Endocrinol. Metab. 88: 922, 1995.
17. Podda M., Ghezzi C., Battezzani P.M., Crosignani A., Zuin M., Roda A. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 98: 1044, 1990.
18. Baudin E., Marcellin P., Pouteau M., Colas-Linhart N., Le Floch J.P., Lemonnier C. et al. Reversibility of thyroid dysfunction induced by recombinant alpha-interferon in chronic hepatitis C. Clin. Endocrinol. 39: 657, 1993.
19. Saracco G., Touscoz A., Durazzo M., Rosina F., Donegani E., Chiandussi L., Gallo V. Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis. J. Hepatol. 11: 339, 1990.
20. Custro N., Scafidi V., Lo Baido R., Nastri L., Abbate G., Cuffaro M.P., Gallo S., Vienna G., Notarbartolo A. Subclinical hypothyroidism resulting from autoimmune thyroiditis in female patients with endogenous depression. J. Endocrinol. Invest. 17: 641, 1994.
21. Bjoro T., Gaarder P.I, Smeland E.B., Kornstad L. Thyroid antibodies in blood donors: prevalence and clinical significance. Acta Endocrinol. 105: 324, 1984.
22. Dalekos G.N., Manoussakis M.N., Goussia A.C., Tsianos E.V., Moutsopoulos H.M. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies and other autoantibodies in patients with ulcerative colitis. Gut 34: 658, 1993.
23. Pateron D., Hartmann D.J., Duclos-Vallée J.C., Jouanolle H., Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J. Hepatol. 16: 244, 1992.
24. Quaranta J.F., Tran A., Regnier D., Lestestu R., Beusnel C., Fuzibet J.G. High prevalence of antibodies to hepatitis C virus HCV in patients with antithyroid autoantibodies. J. Hepatol. 18: 136, 1993.
25. Vento S., Eddlestone A.L. Immunological aspects of chronic active hepatitis. Clin. Exp. Immunol. 68: 225, 1987.
26. Pinchera A., Fenzi G.F., Bartalena L., Chiovato L., Marcocci C. Thyroiditis. In: de Visscher M. (Ed.), The thyroid gland. Raven Press, New York, 1990, p.413.
27. Marcellin P., Pouteau M., Benhamon J.P. Hepatitis-C virus infection, alpha interferon therapy and thyroid dysfunction. J. Hepatol. 22: 364, 1995.
28. Burman P., Totterman T.H., Oberg K., Anders Karlsson F. Thyroid autoimmunity in patients on long-term therapy with leukocyte-derived interferon. J. Clin. Endocrinol. Metab. 63: 1086, 1986.
29. Fentiman L.S., Balkwill F.R., Thomas B.S., Russel M.J., Todd I., Bottazzo G.F. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur. J. Cancer Clin. Oncol. 24: 1299, 1988.
30. Kodama T., Katabami S., Kamijo K., Katanuma A., Yamashita K., Azuma N., Tamaki T., Yachi A. Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon. J. Gastroenterol. 29: 289, 1994.